Abstract

Proteasomes are multisubunit enzyme complexes. They contain three enzymatic active sites which are termed chymotrypsin-like, trypsin-like, and caspase-like. The elementary function of the proteasomes is degradation of damaged proteins. Proteasome inhibition leads to accumulation of damaged protein, which leads to caspase activation and cell death. This relationship is used in cancer therapy. Bortezomib is the first proteasome inhibitor approved by the US Food and Drug Administration for the treatment of relapsed/refractory multiple myeloma. Carfilzomib belongs to the second generation of drugs, which was approved by the US FDA in 2012. Currently in the study phase there are four new inhibitors: ixazomib (MLN9780/MLN2238), delanzomib (CEP-18770), oprozomib (ONX0912/PR-047) and marizomib (NPI-0052).

References

• 1. Adams J.: Development of the proteasome inhibitor PS-341. Oncologist,2002; 7: 9-16
  Google Scholar
• 1. Adams J.: Development of the proteasome inhibitor PS-341. Oncologist,2002; 7: 9-16
  Google Scholar
• 2. Adams J.: The proteasome: structure, function, and role in thecell. Cancer Treat. Rev., 2003; 29 (Suppl. 1): 3-9
  Google Scholar
• 2. Adams J.: The proteasome: structure, function, and role in thecell. Cancer Treat. Rev., 2003; 29 (Suppl. 1): 3-9
  Google Scholar
• 3. Allegra A., Alonci A., Gerace D., Russo S., Innao V., Calabrò L.,Musolino C.: New orally active proteasome inhibitors in multiplemyeloma. Leuk. Res., 2014; 38: 1-9
  Google Scholar
• 3. Allegra A., Alonci A., Gerace D., Russo S., Innao V., Calabrò L.,Musolino C.: New orally active proteasome inhibitors in multiplemyeloma. Leuk. Res., 2014; 38: 1-9
  Google Scholar
• 4. Arastu-Kapur S., Anderl J.L., Kraus M., Parlati F., Shenk K.D., LeeS.J., Muchamuel T., Bennett M.K., Driessen C., Ball A.J., Kirk C.J.:Nonproteasomal targets of the proteasome inhibitors bortezomiband carfilzomib: a link to clinical adverse events. Clin. Cancer Res.,2011; 17: 2734-2743
  Google Scholar
• 4. Arastu-Kapur S., Anderl J.L., Kraus M., Parlati F., Shenk K.D., LeeS.J., Muchamuel T., Bennett M.K., Driessen C., Ball A.J., Kirk C.J.:Nonproteasomal targets of the proteasome inhibitors bortezomiband carfilzomib: a link to clinical adverse events. Clin. Cancer Res.,2011; 17: 2734-2743
  Google Scholar
• 5. Bacco A.D., Berger A., Gupta N., Gao F., Blakemore S., Qian M.,Chen S., Stringer B., Yang Y., Liu R., Tirrell S., Bowman D., SmithD.C., Sullivan D., Infante J.R. i wsp.: Tumor drug distribution andtarget engagement of MLN9708, an investigational proteasome inhibitor,in patients with advanced solid tumors. J. Clin. Oncol., 2012; 30 (Suppl.): 3077 (abstr.)
  Google Scholar
• 5. Bacco A.D., Berger A., Gupta N., Gao F., Blakemore S., Qian M.,Chen S., Stringer B., Yang Y., Liu R., Tirrell S., Bowman D., SmithD.C., Sullivan D., Infante J.R. i wsp.: Tumor drug distribution andtarget engagement of MLN9708, an investigational proteasome inhibitor,in patients with advanced solid tumors. J. Clin. Oncol., 2012; 30 (Suppl.): 3077 (abstr.)
  Google Scholar
• 6. Badros A.Z., Vij R., Martin T., Zonder J.A., Kunkel L., Wang Z.,Lee S., Wong A.F., Niesvizky R.: Carfilzomib in multiple myelomapatients with renal impairment: pharmacokinetics and safety. Leukemia,2013; 27: 1707-1714
  Google Scholar
• 6. Badros A.Z., Vij R., Martin T., Zonder J.A., Kunkel L., Wang Z.,Lee S., Wong A.F., Niesvizky R.: Carfilzomib in multiple myelomapatients with renal impairment: pharmacokinetics and safety. Leukemia,2013; 27: 1707-1714
  Google Scholar
• 7. Bold R.J., Virudachalam S., McConkey D.J.: Chemosensitizationof pancreatic cancer by inhibition of the 26S proteasome. J. Surg.Res., 2001; 100: 11-17
  Google Scholar
• 7. Bold R.J., Virudachalam S., McConkey D.J.: Chemosensitizationof pancreatic cancer by inhibition of the 26S proteasome. J. Surg.Res., 2001; 100: 11-17
  Google Scholar
• 8. Bury M., Niemierko A.: Proteasomalna degradacja białek komórkowych.Postępy Biol. Kom., 2005; 32: 435-448
  Google Scholar
• 8. Bury M., Niemierko A.: Proteasomalna degradacja białek komórkowych.Postępy Biol. Kom., 2005; 32: 435-448
  Google Scholar
• 9. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M.,Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., NicholsonB., Chao T.H., Neuteboom S.T., Richardson P., Palladino M.A.,Anderson K.C.: A novel orally active proteasome inhibitor inducesapoptosis in multiple myeloma cells with mechanisms distinct fromBortezomib. Cancer Cell, 2005; 8: 407-419
  Google Scholar
• 9. Chauhan D., Catley L., Li G., Podar K., Hideshima T., Velankar M.,Mitsiades C., Mitsiades N., Yasui H., Letai A., Ovaa H., Berkers C., NicholsonB., Chao T.H., Neuteboom S.T., Richardson P., Palladino M.A.,Anderson K.C.: A novel orally active proteasome inhibitor inducesapoptosis in multiple myeloma cells with mechanisms distinct fromBortezomib. Cancer Cell, 2005; 8: 407-419
  Google Scholar
• 10. Chauhan D., Singh A.V., Aujay M., Kirk C.J., Bandi M., CiccarelliB., Raje N., Richardson P., Anderson K.C.: A novel orally active proteasomeinhibitor ONX0912 triggers in vitro and in vivo cytotoxicityin multiple myeloma. Blood, 2010; 116: 4906-4915
  Google Scholar
• 10. Chauhan D., Singh A.V., Aujay M., Kirk C.J., Bandi M., CiccarelliB., Raje N., Richardson P., Anderson K.C.: A novel orally active proteasomeinhibitor ONX0912 triggers in vitro and in vivo cytotoxicityin multiple myeloma. Blood, 2010; 116: 4906-4915
  Google Scholar
• 11. Chauhan D., Singh A.V., Ciccarelli B., Richardson P.G., PalladinoM.A., Anderson K.C.: Combination of novel proteasome inhibitorNPI-0052 and lenalidomide trigger in vitro and in vivo synergisticcytotoxicity in multiple myeloma. Blood, 2010; 115: 834-845
  Google Scholar
• 11. Chauhan D., Singh A.V., Ciccarelli B., Richardson P.G., PalladinoM.A., Anderson K.C.: Combination of novel proteasome inhibitorNPI-0052 and lenalidomide trigger in vitro and in vivo synergisticcytotoxicity in multiple myeloma. Blood, 2010; 115: 834-845
  Google Scholar
• 12. Chauhan D., Tian Z., Zhou B., Kuhn D., Orlowski R., Raje N., RichardsonP., Anderson K.C.: In vitro and in vivo selective antitumor activityof a novel orally bioavailable proteasome inhibitor MLN9708against multiple myeloma cells. Clin. Cancer Res., 2011; 17: 5311-5321
  Google Scholar
• 12. Chauhan D., Tian Z., Zhou B., Kuhn D., Orlowski R., Raje N., RichardsonP., Anderson K.C.: In vitro and in vivo selective antitumor activityof a novel orally bioavailable proteasome inhibitor MLN9708against multiple myeloma cells. Clin. Cancer Res., 2011; 17: 5311-5321
  Google Scholar
• 13. Dajee M, Aujay M, Demo S, Jiang J., Krik C., Lee S., Parlati F., SheildJ., Sun M., Suzuki E.: The selective proteasome inhibitor carfilzomibin combination with chemotherapeutic agents improves anti-tumorresponse in solid tumor xenograft models. Eur. J. Cancer, 2008; 6(Suppl.): 75
  Google Scholar
• 13. Dajee M, Aujay M, Demo S, Jiang J., Krik C., Lee S., Parlati F., SheildJ., Sun M., Suzuki E.: The selective proteasome inhibitor carfilzomibin combination with chemotherapeutic agents improves anti-tumorresponse in solid tumor xenograft models. Eur. J. Cancer, 2008; 6(Suppl.): 75
  Google Scholar
• 14. Dasmahapatra G., Lembersky D., Son M.P., Attkisson E., Dent P.,Fisher R.I., Friedberg J.W., Grant S.: Carfilzomib interacts synergisticallywith histone deacetylase inhibitors in mantle cell lymphomacells in vitro and in vivo. Mol. Cancer Ther., 2011; 10: 1686-1697
  Google Scholar
• 14. Dasmahapatra G., Lembersky D., Son M.P., Attkisson E., Dent P.,Fisher R.I., Friedberg J.W., Grant S.: Carfilzomib interacts synergisticallywith histone deacetylase inhibitors in mantle cell lymphomacells in vitro and in vivo. Mol. Cancer Ther., 2011; 10: 1686-1697
  Google Scholar
• 15. Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N.,Jiang J., Laidig G.J., Lewis E.R., Parlati F., Shenk K.D., Smyth M.S., SunC.M., Vallone M.K., Woo T.M., Molineaux C.J., Bennett M.K.: Antitumoractivity of PR-171, a novel irreversible inhibitor of the proteasome.Cancer Res., 2007; 67: 6383-6391
  Google Scholar
• 15. Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N.,Jiang J., Laidig G.J., Lewis E.R., Parlati F., Shenk K.D., Smyth M.S., SunC.M., Vallone M.K., Woo T.M., Molineaux C.J., Bennett M.K.: Antitumoractivity of PR-171, a novel irreversible inhibitor of the proteasome.Cancer Res., 2007; 67: 6383-6391
  Google Scholar
• 16. Escarega E.O., Fuentes-Alexandro S., Garcia-Carrasco M., GaticaA., Zamora A.: The transcription nuclear factor-kappa B and cancer.Clin. Oncol., 2007; 19: 154-161
  Google Scholar
• 16. Escarega E.O., Fuentes-Alexandro S., Garcia-Carrasco M., GaticaA., Zamora A.: The transcription nuclear factor-kappa B and cancer.Clin. Oncol., 2007; 19: 154-161
  Google Scholar
• 17. Frankel A., Man S., Elliott P., Adams J., Kerbel R.S.: Lack of multicellulardrug resistance observed in human ovarian and prostatecarcinoma treated with the proteasome inhibitor PS-341. Clin. CancerRes., 2000; 6: 3719-3728
  Google Scholar
• 17. Frankel A., Man S., Elliott P., Adams J., Kerbel R.S.: Lack of multicellulardrug resistance observed in human ovarian and prostatecarcinoma treated with the proteasome inhibitor PS-341. Clin. CancerRes., 2000; 6: 3719-3728
  Google Scholar
• 18. Gallerani E., Zucchetti M., Brunelli D., Marangon E., NoberascoC., Hess D., Delmonte A., Martinelli G., Böhm S., Driessen C., DeBraud F., Marsoni S., Cereda R., Sala F., D’Incalci M., Sessa C.: A firstin human phase I study of the proteasome inhibitor CEP-18770 inpatients with advanced solid tumours and multiple myeloma. Eur.J. Cancer, 2013; 49: 290-296
  Google Scholar
• 18. Gallerani E., Zucchetti M., Brunelli D., Marangon E., NoberascoC., Hess D., Delmonte A., Martinelli G., Böhm S., Driessen C., DeBraud F., Marsoni S., Cereda R., Sala F., D’Incalci M., Sessa C.: A firstin human phase I study of the proteasome inhibitor CEP-18770 inpatients with advanced solid tumours and multiple myeloma. Eur.J. Cancer, 2013; 49: 290-296
  Google Scholar
• 19. Garcia-Gomez A., Quwaider D., Canaveses M., Ocio E.M., Tian Z.,Blanco J.F., Berger A.J., Ortiz-de-Solorzano C., Hernández-Iglesias T.,Martens A.C., Groen R.W., Mateo-Urdiales J., Fraile S., Galarraga M.,Chauhan D., San Miguel J.F., Raje N., Garayoa M.: Preclinical activityof the oral proteasome inhibitor MLN9708 in myeloma bone disease.Clin. Cancer Res., 2014; 20: 1542-1554
  Google Scholar
• 19. Garcia-Gomez A., Quwaider D., Canaveses M., Ocio E.M., Tian Z.,Blanco J.F., Berger A.J., Ortiz-de-Solorzano C., Hernández-Iglesias T.,Martens A.C., Groen R.W., Mateo-Urdiales J., Fraile S., Galarraga M.,Chauhan D., San Miguel J.F., Raje N., Garayoa M.: Preclinical activityof the oral proteasome inhibitor MLN9708 in myeloma bone disease.Clin. Cancer Res., 2014; 20: 1542-1554
  Google Scholar
• 20. Groll M., Heinemeyer W., Jäger S., Ullrich T., Bochtler M., WolfD.H., Huber R.: The catalytic sites of 20S proteasomes and their rolein subunit maturation: a mutational and crystallographic study. Proc.Natl. Acad. Sci. USA, 1999; 96: 10976-10983
  Google Scholar
• 20. Groll M., Heinemeyer W., Jäger S., Ullrich T., Bochtler M., WolfD.H., Huber R.: The catalytic sites of 20S proteasomes and their rolein subunit maturation: a mutational and crystallographic study. Proc.Natl. Acad. Sci. USA, 1999; 96: 10976-10983
  Google Scholar
• 21. Hideshima T., Richardson P., Chauhan D., Palombella V.J., ElliottP.J., Adams J., Anderson K.C.: The proteasome inhibitor PS-341inhibits growth, induces apoptosis, and overcomes drug resistancein human multiple myeloma cells. Cancer Res., 2001; 61: 3071-3076
  Google Scholar
• 21. Hideshima T., Richardson P., Chauhan D., Palombella V.J., ElliottP.J., Adams J., Anderson K.C.: The proteasome inhibitor PS-341inhibits growth, induces apoptosis, and overcomes drug resistancein human multiple myeloma cells. Cancer Res., 2001; 61: 3071-3076
  Google Scholar
• 22. Jakob C., Egerer K., Liebisch P., Türkmen S., Zavrski I., KuckelkornU., Heider U., Kaiser M., Fleissner C., Sterz J., Kleeberg L., FeistE., Burmester G.R., Kloetzel P.M., Sezer O.: Circulating proteasomelevels are an independent prognostic factor for survival in multiplemyeloma. Blood, 2007; 109: 2100-2105
  Google Scholar
• 22. Jakob C., Egerer K., Liebisch P., Türkmen S., Zavrski I., KuckelkornU., Heider U., Kaiser M., Fleissner C., Sterz J., Kleeberg L., FeistE., Burmester G.R., Kloetzel P.M., Sezer O.: Circulating proteasomelevels are an independent prognostic factor for survival in multiplemyeloma. Blood, 2007; 109: 2100-2105
  Google Scholar
• 23. Jurczyszyn A., Skotnicki A.B.: Proteasome inhibition as a noveltherapeutic target in neoplasmatic diseases. Adv. Clin. Exp. Med.,2006; 15: 309-320
  Google Scholar
• 23. Jurczyszyn A., Skotnicki A.B.: Proteasome inhibition as a noveltherapeutic target in neoplasmatic diseases. Adv. Clin. Exp. Med.,2006; 15: 309-320
  Google Scholar
• 24. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., SunC.M., Demo S.D., Bennett M.K., van Leeuwen F.W., Chanan-Khan A.A.,Orlowski R.Z.: Potent activity of carfilzomib, a novel, irreversibleinhibitor of the ubiquitin-proteasome pathway, against preclinicalmodels of multiple myeloma. Blood, 2007; 110: 3281-3290
  Google Scholar
• 24. Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., SunC.M., Demo S.D., Bennett M.K., van Leeuwen F.W., Chanan-Khan A.A.,Orlowski R.Z.: Potent activity of carfilzomib, a novel, irreversibleinhibitor of the ubiquitin-proteasome pathway, against preclinicalmodels of multiple myeloma. Blood, 2007; 110: 3281-3290
  Google Scholar
• 25. Kumar S, Bensinger W, Reeder CB, Zimmerman T.M., BerensonJ.R., Liu G., Berg D., Gupta N., Di Bacco A., Hui A.M., NiesvizkyR.: Weekly dosing of the investigational oral proteasome inhibitorMLN9708 in patients (pts) with relapsed/refractory multiple myeloma(MM): A phase I study. J. Clin. Oncol., 2012; 30 (suppl.): abstr. 8034
  Google Scholar
• 25. Kumar S, Bensinger W, Reeder CB, Zimmerman T.M., BerensonJ.R., Liu G., Berg D., Gupta N., Di Bacco A., Hui A.M., NiesvizkyR.: Weekly dosing of the investigational oral proteasome inhibitorMLN9708 in patients (pts) with relapsed/refractory multiple myeloma(MM): A phase I study. J. Clin. Oncol., 2012; 30 (suppl.): abstr. 8034
  Google Scholar
• 26. Kupperman E., Lee E.C., Cao Y., Bannerman B., Fitzgerald M.,Berger A., Yu J., Yang Y., Hales P., Bruzzese F., Liu J., Blank J., GarciaK., Tsu C., Dick L., Fleming P., Yu L., Manfredi M., Rolfe M., Bolen J.:Evaluation of the proteasome inhibitor MLN9708 in preclinical modelsof human cancer. Cancer Res., 2010; 70: 1970-1980
  Google Scholar
• 26. Kupperman E., Lee E.C., Cao Y., Bannerman B., Fitzgerald M.,Berger A., Yu J., Yang Y., Hales P., Bruzzese F., Liu J., Blank J., GarciaK., Tsu C., Dick L., Fleming P., Yu L., Manfredi M., Rolfe M., Bolen J.:Evaluation of the proteasome inhibitor MLN9708 in preclinical modelsof human cancer. Cancer Res., 2010; 70: 1970-1980
  Google Scholar
• 27. Li W., Tu D., Brunger A.T., Ye Y.: A ubiquitin ligase transfers preformedpolyubiqutin chains from a conjugating enzyme to a substrate.Nature, 2007; 446: 333-337
  Google Scholar
• 27. Li W., Tu D., Brunger A.T., Ye Y.: A ubiquitin ligase transfers preformedpolyubiqutin chains from a conjugating enzyme to a substrate.Nature, 2007; 446: 333-337
  Google Scholar
• 28. Maliński M., Cichocki M.: Inhibicja aktywności proteasomu jakonowa strategia w terapii i chemioprewencji nowotworów. PostępyHig. Med. Dośw., 2013; 67: 90-106
  Google Scholar
• 28. Maliński M., Cichocki M.: Inhibicja aktywności proteasomu jakonowa strategia w terapii i chemioprewencji nowotworów. PostępyHig. Med. Dośw., 2013; 67: 90-106
  Google Scholar
• 29. Martin P., Chang J.E., Rifkin R.M., Hui A.M., Berg D., Gupta N., LiuG., Di Bacco A., Assouline S.E.: MLN9708, an investigational proteasomeinhibitor, in patients (pts) with relapsed/refractory lymphoma:emerging data from a phase I dose-escalation study. J. Clin. Oncol.,2012; 30 (Suppl.): 8064 (abstr.)
  Google Scholar
• 29. Martin P., Chang J.E., Rifkin R.M., Hui A.M., Berg D., Gupta N., LiuG., Di Bacco A., Assouline S.E.: MLN9708, an investigational proteasomeinhibitor, in patients (pts) with relapsed/refractory lymphoma:emerging data from a phase I dose-escalation study. J. Clin. Oncol.,2012; 30 (Suppl.): 8064 (abstr.)
  Google Scholar
• 30. Miller Z., Ao L., Kim K.B., Lee W.: Inhibitors of the immunoproteasome:current status and future directions. Curr. Pharm. Des.,2013; 19: 4140-4151
  Google Scholar
• 30. Miller Z., Ao L., Kim K.B., Lee W.: Inhibitors of the immunoproteasome:current status and future directions. Curr. Pharm. Des.,2013; 19: 4140-4151
  Google Scholar
• 31. Moreau P., Richardson P.G., Cavo M., Orlowski R.Z., San MiguelJ.F., Palumbo A., Harousseau J.L.: Proteasome inhibitors in multiplemyeloma: 10 years later. Blood, 2012; 120: 947-959
  Google Scholar
• 31. Moreau P., Richardson P.G., Cavo M., Orlowski R.Z., San MiguelJ.F., Palumbo A., Harousseau J.L.: Proteasome inhibitors in multiplemyeloma: 10 years later. Blood, 2012; 120: 947-959
  Google Scholar
• 32. Nagy V., Dikic I.: Ubiquitin ligase complexes: from substrate selectionto conjugational specificity. Biol. Chem., 2010; 391: 163-169
  Google Scholar
• 32. Nagy V., Dikic I.: Ubiquitin ligase complexes: from substrate selectionto conjugational specificity. Biol. Chem., 2010; 391: 163-169
  Google Scholar
• 33. Oldziej A., Bolkun L., Galar M., Kalita J., Ostrowska H., RomaniukW., Kloczko J.: Assessment of proteasome concentration andchymotrypsin-like activity in plasma of patients with newly diagnosedmultiple myeloma. Leuk. Res., 2014; 38: 925-930
  Google Scholar
• 33. Oldziej A., Bolkun L., Galar M., Kalita J., Ostrowska H., RomaniukW., Kloczko J.: Assessment of proteasome concentration andchymotrypsin-like activity in plasma of patients with newly diagnosedmultiple myeloma. Leuk. Res., 2014; 38: 925-930
  Google Scholar
• 34. Orlowski M., Wilk S.: Catalytic activites of the 20S proteasome,a multicatalytic proteinase complex. Arch. Biochem. Biophys., 2000;383: 1-16
  Google Scholar
• 34. Orlowski M., Wilk S.: Catalytic activites of the 20S proteasome,a multicatalytic proteinase complex. Arch. Biochem. Biophys., 2000;383: 1-16
  Google Scholar
• 35. Papadopoulos K.P., Mendelson D., Tolcher A.W., Patnaik A., BurrisH.A., Rasco D., Bendell J.C., Gordon M., Kato G., Wong H., BombaD., Lee S., Gillenwater H.H., Woo T., Infante J.: A phase I, open-label,dose-escalation study of the novel oral proteasome inhibitor ONX
  Google Scholar
• 35. Papadopoulos K.P., Mendelson D., Tolcher A.W., Patnaik A., BurrisH.A., Rasco D., Bendell J.C., Gordon M., Kato G., Wong H., BombaD., Lee S., Gillenwater H.H., Woo T., Infante J.: A phase I, open-label,dose-escalation study of the novel oral proteasome inhibitor ONX
  Google Scholar
• 36. Paul S.: Dysfunction of the ubiquitin-proteasome system in multipledisease conditions: therapeutic approaches. Bioessays, 2008;30: 1172-1184
  Google Scholar
• 36. Paul S.: Dysfunction of the ubiquitin-proteasome system in multipledisease conditions: therapeutic approaches. Bioessays, 2008;30: 1172-1184
  Google Scholar
• 37. Paulus A., Masood A., Miller K.C., Khan A.N., Akhtar D., AdvaniP., Foran J., Rivera C., Roy V., Colon-Otero G., Chitta K., Chanan-KhanA.: The investigational agent MLN2238 induces apoptosis and iscytotoxic to CLL cells in vitro, as a single agent and in combinationwith other drugs. Br. J. Haematol., 2014; 165: 78-88
  Google Scholar
• 37. Paulus A., Masood A., Miller K.C., Khan A.N., Akhtar D., AdvaniP., Foran J., Rivera C., Roy V., Colon-Otero G., Chitta K., Chanan-KhanA.: The investigational agent MLN2238 induces apoptosis and iscytotoxic to CLL cells in vitro, as a single agent and in combinationwith other drugs. Br. J. Haematol., 2014; 165: 78-88
  Google Scholar
• 38. Piva R., Reggeri B., Williams M., Costa G., Tamagno I., Ferrero D.,Giai V., Coscia M., Peola S., Massaia M., Pezzoni G., Allievi C., PescalliN., Cassin M., di Giovine S. i wsp.: CEP-18770 a novel, orally activeproteasome inhibitor with a tumor-selective pharmacologic profilecompetitive with bortezomib. Blood, 2008; 111: 2765-2775
  Google Scholar
• 38. Piva R., Reggeri B., Williams M., Costa G., Tamagno I., Ferrero D.,Giai V., Coscia M., Peola S., Massaia M., Pezzoni G., Allievi C., PescalliN., Cassin M., di Giovine S. i wsp.: CEP-18770 a novel, orally activeproteasome inhibitor with a tumor-selective pharmacologic profilecompetitive with bortezomib. Blood, 2008; 111: 2765-2775
  Google Scholar
• 39. Potts B.C., Lam K.S.: Generating a generation of proteasomeinhibitors: from microbial fermentation to total synthesis of salinosporamideA (Marizomib) and other salinosporamides. Mar. Drugs,2010; 8: 835-880
  Google Scholar
• 39. Potts B.C., Lam K.S.: Generating a generation of proteasomeinhibitors: from microbial fermentation to total synthesis of salinosporamideA (Marizomib) and other salinosporamides. Mar. Drugs,2010; 8: 835-880
  Google Scholar
• 40. Qureshi N., Vogel S.N., Van Way C.3rd, Papasian C.J., QureshiA.A., Morrison D.C.: The proteasome: a central regulator of inflammationand macrophage function. Immunol. Res., 2005; 31: 243-260
  Google Scholar
• 40. Qureshi N., Vogel S.N., Van Way C.3rd, Papasian C.J., QureshiA.A., Morrison D.C.: The proteasome: a central regulator of inflammationand macrophage function. Immunol. Res., 2005; 31: 243-260
  Google Scholar
• 41. Richardson P.G., Berdeja J.G., Niesvizky R., Lonial S., Roy V., HariP., Berg D., Liu G., Gupta N., Di Bacco A., Hui A.M., Kumar S.: Oralweekly MLN9708, an investigational proteasome inhibitor, in combinationwith lenalidomide and dexamethasone in patients (pts) withpreviously untreated multiple myeloma (MM): A phase I/II study. J.Clin. Oncol., 2012; 30(Suppl.): 8033 (abstr.)
  Google Scholar
• 41. Richardson P.G., Berdeja J.G., Niesvizky R., Lonial S., Roy V., HariP., Berg D., Liu G., Gupta N., Di Bacco A., Hui A.M., Kumar S.: Oralweekly MLN9708, an investigational proteasome inhibitor, in combinationwith lenalidomide and dexamethasone in patients (pts) withpreviously untreated multiple myeloma (MM): A phase I/II study. J.Clin. Oncol., 2012; 30(Suppl.): 8033 (abstr.)
  Google Scholar
• 42. Richardson P.G., Mitsiades C., Schlossman R., Ghobrial I., HideshimaT., Munshi N., Anderson K.C.: Bortezomib in the front-line treatmentof multiple myeloma. Expert Rev. Anticancer Ther., 2008; 8:1053-1072
  Google Scholar
• 42. Richardson P.G., Mitsiades C., Schlossman R., Ghobrial I., HideshimaT., Munshi N., Anderson K.C.: Bortezomib in the front-line treatmentof multiple myeloma. Expert Rev. Anticancer Ther., 2008; 8:1053-1072
  Google Scholar
• 43. Richardson P.G., Spencer A., Cannell P., Harrison S.J., Catley L.,Underhill C., Zimmerman T.M., Hofmeister C.C., Jakubowiak A.J.,Laubach J.P., Palladino M.A., Longenecker A.M., Lay A., Wear S., LloydG.K. i wsp.: Phase I clinical evaluation of twice-weekly marizomib(NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts,2011; 118: 302
  Google Scholar
• 43. Richardson P.G., Spencer A., Cannell P., Harrison S.J., Catley L.,Underhill C., Zimmerman T.M., Hofmeister C.C., Jakubowiak A.J.,Laubach J.P., Palladino M.A., Longenecker A.M., Lay A., Wear S., LloydG.K. i wsp.: Phase I clinical evaluation of twice-weekly marizomib(NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts,2011; 118: 302
  Google Scholar
• 44. Sanchez E., Li M., Li J., Wang C., Chen H., Jones-Bolin S., HunterK., Ruggeri B., Berenson J.R.: CEP-18770 (delanzomib) in combinationwith dexamethasone and lenalidomide inhibits the growth ofmultiple myeloma. Leuk. Res., 2012; 36: 1422-1427
  Google Scholar
• 44. Sanchez E., Li M., Li J., Wang C., Chen H., Jones-Bolin S., HunterK., Ruggeri B., Berenson J.R.: CEP-18770 (delanzomib) in combinationwith dexamethasone and lenalidomide inhibits the growth ofmultiple myeloma. Leuk. Res., 2012; 36: 1422-1427
  Google Scholar
• 45. Sanchez E., Li M., Steinberg J.A., Wang C., Shen J., Bonavida B.,Li Z.W., Chen H., Berenson J.R.: The proteasome inhibitor CEP-18770enhances the anti-myeloma activity of bortezomib and melphalan.Br. J. Haematol., 2010; 148: 569-581
  Google Scholar
• 45. Sanchez E., Li M., Steinberg J.A., Wang C., Shen J., Bonavida B.,Li Z.W., Chen H., Berenson J.R.: The proteasome inhibitor CEP-18770enhances the anti-myeloma activity of bortezomib and melphalan.Br. J. Haematol., 2010; 148: 569-581
  Google Scholar
• 46. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A.,Elliott P.J., Adams J., Callery M.P.: 26S proteasome inhibition inducesapoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem.,2001; 82: 110-122
  Google Scholar
• 46. Shah S.A., Potter M.W., McDade T.P., Ricciardi R., Perugini R.A.,Elliott P.J., Adams J., Callery M.P.: 26S proteasome inhibition inducesapoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem.,2001; 82: 110-122
  Google Scholar
• 47. Siegel D.S., Martin T., Wang M., Vij R., Jakubowiak A.J., Lonial S.,Trudel S., Kukreti V., Bahlis N., Alsina M., Chanan-Khan A., Buadi F.,Reu F.J., Somlo G., Zonder J. i wsp.: A phase 2 study of single-agentcarfilzomib (PX-171-003-A1) in patients with relapsed and refractorymultiple myeloma. Blood, 2012; 120: 2817-2825
  Google Scholar
• 47. Siegel D.S., Martin T., Wang M., Vij R., Jakubowiak A.J., Lonial S.,Trudel S., Kukreti V., Bahlis N., Alsina M., Chanan-Khan A., Buadi F.,Reu F.J., Somlo G., Zonder J. i wsp.: A phase 2 study of single-agentcarfilzomib (PX-171-003-A1) in patients with relapsed and refractorymultiple myeloma. Blood, 2012; 120: 2817-2825
  Google Scholar
• 48. Smith D.C., Sullivan D., Infante J.R., Kauh J.S., Siu L.L., VlahovicG., Thompson J.A., Gupta N., Di Bacco A., Liu G., KalebicT.: MLN9708,an investigational proteasome inhibitor, in patients (pts) with solidtumors: Update phase I results. J. Clin. Oncol., 2012; 30 (suppl.): abstr.e13603
  Google Scholar
• 48. Smith D.C., Sullivan D., Infante J.R., Kauh J.S., Siu L.L., VlahovicG., Thompson J.A., Gupta N., Di Bacco A., Liu G., KalebicT.: MLN9708,an investigational proteasome inhibitor, in patients (pts) with solidtumors: Update phase I results. J. Clin. Oncol., 2012; 30 (suppl.): abstr.e13603
  Google Scholar
• 49. Spencer A., Millward M., Mainwaring P., Harrison S., Catley L.,Townsend A., Sukumaran S., Longenecker A.M., Palladino M.A., LloydG.K., Neuteboom S., Padrik P., Spear M.A., Price T.: Phase I clinicaltrial of the novel structure proteasome inhibitor NPI-0052. ASH AnnualMeeting Abstract, 2009; 114: 2693
  Google Scholar
• 49. Spencer A., Millward M., Mainwaring P., Harrison S., Catley L.,Townsend A., Sukumaran S., Longenecker A.M., Palladino M.A., LloydG.K., Neuteboom S., Padrik P., Spear M.A., Price T.: Phase I clinicaltrial of the novel structure proteasome inhibitor NPI-0052. ASH AnnualMeeting Abstract, 2009; 114: 2693
  Google Scholar
• 50. Stewart A.K., Rajkumar S.V., Dimopoulos M.A., Masszi T., SpickaI., Oriol A., Hájek R., Rosinol L., Siegel D.S., Mihaylov G.G., GoranovaMarinovaV., Rajnics P., Suvorov A., Niesvizky R., Jakubowiak A.J.i wsp.: Carfilzomib, lenalidomide, and dexamethasone for relapsedmultiple myeloma. N. Engl. J. Med., 2015; 372: 142-152
  Google Scholar
• 50. Stewart A.K., Rajkumar S.V., Dimopoulos M.A., Masszi T., SpickaI., Oriol A., Hájek R., Rosinol L., Siegel D.S., Mihaylov G.G., GoranovaMarinovaV., Rajnics P., Suvorov A., Niesvizky R., Jakubowiak A.J.i wsp.: Carfilzomib, lenalidomide, and dexamethasone for relapsedmultiple myeloma. N. Engl. J. Med., 2015; 372: 142-152
  Google Scholar
• 51. Sugumar D., Keller J., Vij R.: Targeted treatments for multiplemyeloma: specific role of carfilzomib. Pharmgenomics. Pers. Med.,2015; 8: 23-33
  Google Scholar
• 51. Sugumar D., Keller J., Vij R.: Targeted treatments for multiplemyeloma: specific role of carfilzomib. Pharmgenomics. Pers. Med.,2015; 8: 23-33
  Google Scholar
• 52. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl Bancroft C., SausvilleE., Adams J., Elliott P., Van Waes C.: Novel proteasome inhibitorPS-341 inhibits activation of nuclear factor-κB, cell survival, tumorgrowth, and angiogenesis in squamous cell carcinoma. Clin. CancerRes., 2001; 7: 1419-1428
  Google Scholar
• 52. Sunwoo J.B., Chen Z., Dong G., Yeh N., Crowl Bancroft C., SausvilleE., Adams J., Elliott P., Van Waes C.: Novel proteasome inhibitorPS-341 inhibits activation of nuclear factor-κB, cell survival, tumorgrowth, and angiogenesis in squamous cell carcinoma. Clin. CancerRes., 2001; 7: 1419-1428
  Google Scholar
• 53. US National Institute of Health. ClinicalTrails.gov. 2014. www.clinicaltrial.gov (13.10.2015)
  Google Scholar
• 53. US National Institute of Health. ClinicalTrails.gov. 2014. www.clinicaltrial.gov (13.10.2015)
  Google Scholar
• 54. Vij R., Wang M., Kaufman J.L., Lonial S., Jakubowiak A.J., StewartA.K., Kukreti V., Jagannath S., McDonagh K.T., Alsina M., BahlisN.J., Reu F.J., Gabrail N.Y., Belch A., Matous J.V. i wsp.: An open-label,signle-arm, phase 2 (PX-171-004) study of single agent carfilzomib inbortezomib-naive patients with relapsed and/or refractory multiplemyeloma. Blood, 2012; 119: 5661-5670
  Google Scholar
• 54. Vij R., Wang M., Kaufman J.L., Lonial S., Jakubowiak A.J., StewartA.K., Kukreti V., Jagannath S., McDonagh K.T., Alsina M., BahlisN.J., Reu F.J., Gabrail N.Y., Belch A., Matous J.V. i wsp.: An open-label,signle-arm, phase 2 (PX-171-004) study of single agent carfilzomib inbortezomib-naive patients with relapsed and/or refractory multiplemyeloma. Blood, 2012; 119: 5661-5670
  Google Scholar
• 55. Wang M., Martin T., Bensinger W., Alsina M., Siegel D.S., KavalerchikE., Huang M., Orlowski R.Z., Niesvizky R.: Phase 2 dose-expansionstudy (PX-171-006) of carfilzomib, lenalidomide, and low-dosedexamethasone in relapsed or progressive multiple myeloma. Blood,2013; 122: 3122-3128
  Google Scholar
• 55. Wang M., Martin T., Bensinger W., Alsina M., Siegel D.S., KavalerchikE., Huang M., Orlowski R.Z., Niesvizky R.: Phase 2 dose-expansionstudy (PX-171-006) of carfilzomib, lenalidomide, and low-dosedexamethasone in relapsed or progressive multiple myeloma. Blood,2013; 122: 3122-3128
  Google Scholar
• 912. in patients with advanced refractory or recurrent solid tumors.J. Clin. Oncol., 2011; 29 (Suppl.): 3075 (abstr.)
  Google Scholar
• 912. in patients with advanced refractory or recurrent solid tumors.J. Clin. Oncol., 2011; 29 (Suppl.): 3075 (abstr.)
  Google Scholar

Full text